192 results on '"Overbeck, Tobias"'
Search Results
2. Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)
3. Predictors of lower exercise capacity in patients with cancer
4. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer
5. Response of eosinophilic fasciitis associated with Waldenström macroglobulinemia to rituximab
6. Abstract 13296: Cardiovascular Determinants of Exercise Capacity in Patients With Cancer
7. Symptom relief, prognostic factors, and outcome in patients receiving urgent radiation therapy for superior vena cava syndrome: A single-center retrospective analysis of 21 years’ practice
8. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
9. Therapeutic Patterns and Clinical Outcomes in Limited Disease Small Cell Lung Cancer: A Decade of Analysis at a Tertiary Cancer Center
10. Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis
11. SARS-CoV-2-specific immune responses in elderly and immunosuppressed participants and patients with hematologic disease or checkpoint inhibition in solid tumors: study protocol of the prospective, observational CoCo immune study
12. “SpezPat”- common advance directives versus disease-centred advance directives: a randomised controlled pilot study on the impact on physicians’ understanding of non-small cell lung cancer patients’ end-of-life decisions
13. Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023 with Focus on Targeted Therapies
14. And Yet It Moves: Clinical Outcomes and Motion Management in Stereotactic Body Radiation Therapy (SBRT) of Centrally Located Non-Small Cell Lung Cancer (NSCLC): Shedding Light on the Internal Organ at Risk Volume (IRV) Concept
15. Predicting the Effect of Variants of Unknown Significance in Molecular Tumor Boards with the VUS-Predict Pipeline
16. Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023 with Focus on Perioperative Therapy, Radiotherapy, and Bispecific T-Cell Engagers.
17. Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer.
18. Temporal Characterization and Visualization of Revolving Therapy-Events in Lung Cancer Patients.
19. Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer
20. Outcomes of Multimodal Treatment in Elderly Patients with Localized Non-Small Lung Cancer from a Radiation Oncology Point of View: Special Focus on Low-Dose Cisplatin.
21. Social participation during the COVID-19 pandemic in persons with a high risk for a severe course of COVID-19 – results of a longitudinal, multi-center observational study in Germany
22. Wirkung und Nebenwirkung von Krebstherapien
23. Adressen
24. NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy
25. Management of Aortoesophageal Fistula in a Palliative Patient with Non-Small-Cell Lung Cancer: A Case Report
26. NTRK Gene Fusions in Non-Small-Cell Lung Cancer: Real-World Screening Data of 1068 Unselected Patients
27. Study protocol: a prospective single-center study for non-invasive biomonitoring of renal complications in cancer patients treated with immune checkpoint inhibitors
28. Optimizing the structure of interdisciplinary tumor boards for effective cancer care
29. Ruxolitinib Induces Interleukin 17 and Ameliorates Chronic Mucocutaneous Candidiasis Caused by STAT1 Gain-of-Function Mutation
30. Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2022
31. Prognostic factors in non-small-cell lung cancer: insights from the German crisp registry
32. Cardiovascular and metabolic determinants of quality of life in patients with cancer
33. Leukemia cutis in a patient with chronic myelomonocytic leukemia
34. Leucaemia cutis bei einem Patienten mit chronischer myelomonozytärer Leukämie
35. NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy.
36. Development and Validation of a Questionnaire to Assess Social Participation of High Risk-Adults in Germany During the COVID-19 Pandemic
37. Additional file 1 of SARS-CoV-2-specific immune responses in elderly and immunosuppressed participants and patients with hematologic disease or checkpoint inhibition in solid tumors: study protocol of the prospective, observational CoCo immune study
38. Additional file 2 of 'SpezPat'- common advance directives versus disease-centred advance directives: a randomised controlled pilot study on the impact on physicians’ understanding of non-small cell lung cancer patients’ end-of-life decisions
39. Additional file 1 of 'SpezPat'- common advance directives versus disease-centred advance directives: a randomised controlled pilot study on the impact on physicians’ understanding of non-small cell lung cancer patients’ end-of-life decisions
40. Cardiovascular and metabolic determinants of quality of life in patients with cancer.
41. Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2022.
42. Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery
43. “SpezPat”- common advance directives versus disease-centred advance directives: a randomised controlled pilot study on the impact in physicians’ understanding of patients’ end-of- life decisions
44. Multimodal Treatment of Nasopharyngeal Carcinoma in Children, Adolescents and Young Adults-Extended Follow-Up of the NPC-2003-GPOH Study Cohort and Patients of the Interim Cohort
45. High-Grade Acute Organ Toxicity as Positive Prognostic Factor in Primary Radio(chemo)therapy for Locally Advanced, Inoperable Head and Neck Cancer
46. Nasopharyngeal carcinoma in adults: treatment results after long-term follow-up with special reference to adjuvant interferon-beta in undifferentiated carcinomas
47. Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer
48. Safety run-in results from phase 3 study of canakinumab (CAN) or placebo in combination with pembrolizumab (PEM) plus platinum based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC (CANOPY-1)
49. Neue Therapie-Ansätze beim Bronchialkarzinom
50. Tumorkonferenz I
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.